Krsnaa Diagnostics shareholders have approved the issuance of up to 16,21,000 warrants convertible into equity shares on a preferential basis to the promoter and promoter group.

The special resolution was passed on September 17, 2026, following a remote e-voting process conducted under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The voting concluded at 5:00 pm IST, with Dinesh Birla & Associates appointed as the scrutinizer for the process.

Voting Results Breakdown

The resolution received overwhelming support from promoter shareholders while facing significant dissent from institutional investors. A total of 18,671,556 votes were polled out of 32,438,672 outstanding shares, representing a 57.56% participation rate.

Promoter shareholders holding 8,795,605 shares voted unanimously in favor of the proposal. Among public non-institutional shareholders, who hold the largest share base of 17,712,796, support stood at 99.81%. However, institutional investors, holding 5,930,271 shares, showed notable resistance, with 32.44% voting against the resolution.

What the Numbers Show

The divergence in voting behavior highlights a clear split between retail/non-institutional public shareholders and institutional stakeholders. While the promoter group and retail investors backed the capital raise mechanism, nearly one-third of institutional votes opposed the preferential issuance. This suggests potential concerns among larger funds regarding dilution or valuation terms, despite the overall resolution passing with a comfortable majority of 92.69%.

Procedural Compliance

The postal ballot notice was issued on August 13, 2026, with voting commencing on August 18, 2026. The company circulated a corrigendum on August 28, 2026, allowing shareholders to modify prior votes; however, no modification requests were received by the scrutinizer. The process adhered to MCA circulars mandating electronic-only communication, with notices dispatched via email to registered members.

Krsnaa Diagnostics has executed a concession agreement with the Government of Punjab to develop and operate PET-CT diagnostic facilities. The deal covers four government hospitals under a public-private partnership model.

The company signed the agreement following a Letter of Award dated August 14, 2026, issued by the Department of Health & Family Welfare, acting through the Punjab Health Systems Corporation (PHSC). This marks Krsnaa Diagnostics' formal entry into the PET-CT segment, an area it had previously avoided.

Deal Structure

The project operates under a Design, Build, Finance, Operate, Maintain and Transfer (DBFOT) format. The concession period spans 15 years. Revenue will be generated on a cash-based model, dependent on the actual number of scans performed and applicable user charges.

Strategic Context

Krsnaa Diagnostics stated that the decision to enter this segment follows a measured approach and growing demand for advanced oncology diagnostics. The company aims to leverage its established capabilities in government healthcare partnerships.

Management noted that the long-term concession framework provides revenue visibility. The deal diversifies the company's portfolio beyond its existing diagnostic services while strengthening its cash portfolio of government PPP partnerships across India.

What the Numbers Show

The absence of a fixed upfront consideration highlights the operational risk and reward structure of the deal. Unlike fixed-price contracts, Krsnaa's revenue is directly tied to patient volume and user charges. This structure aligns the company's earnings potential with the utilization rates of the new facilities over the 15-year term.